City College & MSK Partnership for Cancer Care and Community Outreach

1/2 CCNY-MSK Partnership for Cancer Research, Education and Community Outreach

NIH-funded research City College of New York · NIH-11194430

This partnership develops new cancer treatments, tests ways to reduce treatment side effects and help patients keep appointments, uses AI-powered medical interpreting, and builds community education for people affected by cancer.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionCity College of New York NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-11194430 on NIH RePORTER

What this research studies

This collaboration brings together City College of New York and Memorial Sloan Kettering to move lab discoveries toward real-world cancer care while training students and working with local communities. Projects include helping people on immune checkpoint inhibitors manage side effects and stay on treatment, searching for small molecules that target cancer-driving proteins, testing AI-enhanced medical interpreting to improve communication, and studying germline factors that shape lung tumor genomes. Work spans laboratory experiments, clinic-based patient studies, and community outreach programs. You might be asked to participate in symptom-management interventions, provide clinical samples, or take part in communication/interpretation testing.

Who could benefit from this research

Good fit: Ideal participants include people with cancer treated at MSK or affiliated clinics—particularly those on immune checkpoint inhibitors, people with lung cancer, and patients who need medical interpreting services.

Not a fit: Patients with cancers not covered by the partnership projects or those far from New York City may not directly benefit from or be eligible for participation.

Why it matters

Potential benefit: If successful, this work could reduce treatment side effects, improve attendance and communication during care, and lead to more targeted therapies for some cancers.

How similar studies have performed: Aspects build on prior successes—immunotherapy symptom-management and targeted small-molecule approaches have shown promise, while AI-driven medical interpreting and germline-informed tumor profiling are newer but rapidly developing areas.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.